Brentuximab Vedotin Before Autologous Stem Cell Transplant in Treating Patients With Hodgkin Lymphoma
Status:
Completed
Trial end date:
2017-02-01
Target enrollment:
Participant gender:
Summary
This phase II trial studies how well brentuximab vedotin before autologous (taken from an
individual's own cells) stem cell transplant works in treating patients with Hodgkin
lymphoma. Monoclonal antibody-drug conjugates, such as brentuximab vedotin, can block cancer
growth in different ways by targeting certain cells.